Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

Archives of Internal Medicine

Volumn 166, Issue 15, 2006, Pages 1561-1568

  Nides, Mitchell ^a   Oncken, Cheryl ^b   Gonzales, David ^c   Rennard, Stephen ^d   Watsky, Eric J ^e   Anziano, Rich ^e   Reeves, Karen R ^e  

^a Los Angeles Clinical Trials   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4BETA2 NICOTINIC RECEPTOR PARTIAL AGONIST; AMFEBUTAMONE; CARBON MONOXIDE; NICOTINIC AGENT; PLACEBO; UNCLASSIFIED DRUG; VARENICLINE;

ABNORMAL DREAMING; ADULT; AGED; ARTICLE; ASTHENIA; BLOODY DIARRHEA; CLINICAL TRIAL; COMMON CAROTID ARTERY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MALE; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SMOKING CESSATION; STENOSIS; SYNCOPE; TASTE DISORDER; TRANSIENT ISCHEMIC ATTACK; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 33747199571     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.15.1561     Document Type: Article

References (28)

1. Taylor AL, Bettcher DW. WHO Framework Convention on Tobacco Control: a global "good" for public health. Bull World Health Organ. 2000;78:920-929.
2. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847-852.
3. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29-38.
4. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2003;(2):CD000031.
5. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.
6. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res. 2005;7:491-499.
7. Jimenez-Ruiz C, Granda Orive JI. Success rates for nortriptyline. Chest. 2003;124:768-769.
8. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence: Clinical Practice Guideline. Washington, DC: Public Health Service; 2000.
9. National Institute for Clinical Excellence. Guidance on the Use of Nicotine Replacement Therapy (NTR) and Bupropion for Smoking Cessation. Washington, DC: National Institute for Clinical Excellence; March 2002. Technical appraisal report 39.
10. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474-3477.
11. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001;70:439-446.
12. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391:173-177.
13. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029-1032.
14. Scharfenberg G, Benndorf S, Kempe G. Cytisine (Tabex) as a pharmaceutical aid in stopping smoking [in German]. Dtsch Gesundheitsw. 1971;26:463-465.
15. Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol. 1998;6:331-343.
16. Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction. 2004;99:634-640.
17. Clearing the Air: How to Quit Smoking . . . and Quit for Keeps. Bethesda, MD: National Cancer Institute, National Institutes of Health; 1993. NIH publication 95-1647.
18. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289-294.
19. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief ) in laboratory and clinical settings. Nicotine Tob Res. 2001;3:7-16.
20. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Revealing the multidimensional framework of the Minnesota Nicotine Withdrawal Scale. Curr Med Res Opin. 2005;21:749-760.
21. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
22. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
23. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357:1571-1575.
24. Gonzales D, Rennard SI, Nides MA, et al; Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetycholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
25. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
26. Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl). 2006;184:274-285.
27. Rose JE, Behm FM, Westman EC. Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacol Biochem Behav. 2001;68:187-197.
28. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl). 2002;161:1-16.